This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study
by Zacks Equity Research
Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
by Zacks Equity Research
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
by Kinjel Shah
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study
by Zacks Equity Research
Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer
by Zacks Premium Research
The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
by Zacks Equity Research
AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease
by Zacks Equity Research
Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
Merck's Keytruda Combination Gets EC Nod for Kidney Cancer
by Zacks Equity Research
Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $86.05 in the latest trading session, marking a -0.69% move from the prior day.
Top Analyst Reports: Amazon, Merck, PepsiCo & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Amazon (AMZN), Merck (MRK) and PepsiCo (PEP).
AstraZeneca's Lupus Drug Meets Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.
Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
by Zacks Equity Research
A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails
by Zacks Equity Research
IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Why Is Merck (MRK) Up 4.2% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Forget Pfizer, Add These Big Drugmakers to Your Portfolio
by Kinjel Shah
Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.
Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion
by Zacks Equity Research
Bristol-Myers' (BMY) multiple myeloma drug, Empliciti gets approval in Europe in combination with Celgene's Pomalyst in third or later-line settings.
Here's Why Merck (MRK) is Outperforming Its Industry Of Late
by Zacks Equity Research
Merck's shares are up 11.9% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Medicines Company's Inclisiran Succeeds in Pivotal Study
by Zacks Equity Research
The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in a pivotal study. Shares up.
Bristol-Myers Announces Sale of Celgene's Otezla to Amgen
by Zacks Equity Research
Bristol-Myers (BMY) announces that Celgene will sell psoriasis drug, Otezla, to Amgen in connection with the ongoing regulatory approval process.
Top Ranked Growth Stocks to Buy for August 27th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, August 27th.
Esperion's Drugs in Review Hold Potential, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.
Top Ranked Growth Stocks to Buy for August 26th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, August 26th.
Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.